

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number
WO 01/44189 A1

(51) International Patent Classification⁷: C07D 211/32,
295/18, A61K 31/445, 31/495, A61P 11/00, 19/00, 25/00

Great Abington, Cambridge CB1 6GS (GB). MONTANA,
John, Gary [GB/GB]; Celltech R & D Ltd, Granta Park,
Great Abington, Cambridge CB1 6GS (GB).

(21) International Application Number: PCT/GB00/04865

(74) Agent: GILL JENNINGS & EVERY; Broadgate House,
7 Eldon Street, London EC2M 7LH (GB).

(22) International Filing Date:
18 December 2000 (18.12.2000)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

Published:

— With international search report.

(30) Priority Data:
9929979.4 17 December 1999 (17.12.1999) GB

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (*for all designated States except US*): DARWIN DISCOVERY LIMITED [GB/GB]; 216 Bath Road,
Slough, Berkshire SL1 4EN (GB).


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): OWEN, David, Alan
[GB/GB]; Celltech R & D Ltd, Granta Park, Great Abing-
ton, Cambridge CB1 6GS (GB). BAXTER, Andrew, Dou-
glas [GB/GB]; Celltech R & D Ltd, Granta Park, Great
Abington, Cambridge CB1 6GS (GB). WATSON, Robert,
John [GB/GB]; Celltech R & D Ltd, Granta Park, Great
Abington, Cambridge CB1 6GS (GB). HANNAH, Dun-
can, Robert [GB/GB]; Celltech R & D Ltd, Granta Park,



WO 01/44189 A1

(54) Title: HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS



(57) Abstract: Compounds having therapeutic utility are of formula (I), wherein NB₂ is heterocycloalkyl and R¹ and R² are each various substituents or a cyclic group.

HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS

Field of the Invention

This invention relates to hydroxamic acid derivatives, and to their use in medicine.

5 Background to the Invention

Metalloproteinases, including matrix metalloproteinase (MMP), (human fibroblast) collagenase, gelatinase and TNF convertase (TACE), and their modes of action, and also inhibitors thereof and their clinical effects, are described in WO-A-9611209, WO-A-9712902 and WO-A-9719075, the contents of which are incorporated 10 herein by reference. MMP inhibitors may also be useful in the inhibition of other mammalian metalloproteinases such as the adamalysin family (or ADAMs) whose members include TNF convertase (TACE) and ADAM-10, which can cause the release of TNF α from cells, and others, which have been demonstrated to be expressed by human articular cartilage cells and also involved in the destruction of myelin basic protein, a 15 phenomenon associated with multiple sclerosis.


Compounds which have the property of inhibiting the action of metalloproteinases involved in connective tissue breakdown, such as collagenase, stromelysin and gelatinase, have been shown to inhibit the release of TNF both *in vitro* and *in vivo*. See Gearing *et al* (1994), Nature 370:555-557; McGeehan *et al* (1994), Nature 370:558-561; GB-A-20 2268934; and WO-A-9320047. All of these reported inhibitors contain a hydroxamic acid zinc-binding group, as do the imidazole-substituted compounds disclosed in WO-A-9523790. Other compounds that inhibit MMP and/or TNF are described in WO-A-9513289, WO-A-9611209, WO-A-96035687, WO-A-96035711, WO-A-96035712 and WO-A-96035714.

25 Further, somewhat related compounds are disclosed in US-A-5892112, WO-A-9724117 and FR-A-2597865.

Summary of the Invention

Compounds according to the invention are of formula (I):

5



wherein

- 10 R^1 is a group (optionally substituted with R^3) selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, C_{1-6} alkyl-aryl, heteroaryl, C_{1-6} alkyl-heteroaryl, cycloalkyl, C_{1-6} alkyl-cycloalkyl, heterocycloalkyl and C_{1-6} alkyl-heterocycloalkyl; and
- R^2 is H or C_{1-6} alkyl;
- or CR^1R^2 is cycloalkyl or heterocycloalkyl optionally substituted with R^3 or a
- 15 group (optionally substituted with R^3) selected from C_{1-6} alkyl, aryl, C_{1-6} alkyl-aryl, heteroaryl and C_{1-6} alkyl-heteroaryl;
- R^3 is OR^7 , COR^7 , CO_2R^6 , $\text{CON}(\text{R}^7)_2$, $\text{N}(\text{R}^7)_2$, NR^7COR^7 , $\text{NR}^7\text{CON}(\text{R}^7)_2$, $\text{NR}^7\text{CO}_2\text{R}^8$, $\text{NR}^7\text{SO}_2\text{R}^8$, $\text{S}(\text{O})_{0-2}\text{R}^8$ and $\text{SO}_2\text{N}(\text{R}^7)_2$; or cycloimidyl (optionally substituted with R^4)
- 20 R^4 is C_{1-6} alkyl;
- $\text{B}-\text{N}-\text{B}$ is heterocycloalkyl optionally substituted with R^5 or $=\text{NOR}^5$;
- R^5 is H, R^6 or a group (optionally substituted with R^6) selected from C_{1-6} alkyl, aryl, C_{1-6} alkyl-aryl, heteroaryl, C_{1-6} alkyl-heteroaryl, cycloalkyl, C_{1-6} alkyl-cycloalkyl, heterocycloalkyl and C_{1-6} alkyl-heterocycloalkyl;
- 25 R^6 is H or a group selected from $\text{N}(\text{R}^7)_2$, NR^7COR^7 , $\text{NR}^7\text{CON}(\text{R}^7)_2$, $\text{NR}^7\text{CO}_2\text{R}^8$, $\text{NR}^7\text{SO}_2\text{R}^8$, OR^7 , COR^7 , CO_2R^4 , $\text{CON}(\text{R}^7)_2$, $\text{S}(\text{O})_{0-2}\text{R}^8$ and $\text{SO}_2\text{N}(\text{R}^7)_2$;
- R^7 is H or a group selected from C_{1-6} alkyl, aryl, C_{1-6} alkyl-aryl, heteroaryl, C_{1-6} alkyl-heteroaryl, cycloalkyl, C_{1-6} alkyl-cycloalkyl, heterocycloalkyl and C_{1-6} alkyl-heterocycloalkyl, wherein said group is optionally substituted with R^8 , COR^8 , $\text{S}(\text{O})_{0-2}\text{R}^8$,
- 30 CO_2R^8 , OR^8 , CONR^4R^8 , NR^6R^8 or $\text{SO}_2\text{NR}^4\text{R}^8$, and for each case of $\text{N}(\text{R}^7)_2$ the R^7 groups are the same or different or $\text{N}(\text{R}^7)_2$ is heterocycloalkyl optionally substituted with R^8 , COR^8 , $\text{S}(\text{O})_{0-2}\text{R}^8$, CO_2R^8 , OR^8 , CONR^4R^8 , NR^6R^8 or $\text{SO}_2\text{NR}^4\text{R}^8$; and

R^8 is C_{1-6} alkyl, aryl, C_{1-6} alkyl-aryl, heteroaryl or C_{1-6} alkyl-heteroaryl; and the salts, solvates, hydrates, N-oxides, protected amino, protected carboxy and protected hydroxamic acid derivatives thereof.

Description of the Invention

5 Preferred compounds of the invention are those wherein R^1 is C_{1-6} alkyl or CR^1R^2 is heterocycloalkyl.

The compounds of the Examples are particularly preferred.

It will be appreciated that the compounds according to the invention can contain one or more asymmetrically substituted carbon atoms. The presence of one or more of 10 these asymmetric centres in a compound of formula (I) can give rise to stereoisomers, and in each case the invention is to be understood to extend to all such stereoisomers, including enantiomers and diastereomers, and mixtures including racemic mixtures thereof.

15 It will further be appreciated that the compounds according to the invention may contain an oxime. This oxime can give rise to geometrical isomers, and in each case the invention is to be understood to extend to all such isomers and mixtures thereof.

As used in this specification, alone or in combination, the term " C_{1-6} alkyl" refers to straight or branched chain alkyl moiety having from one to six carbon atoms, including for example, methyl, ethyl, propyl, isopropyl, butyl, *tert*-butyl, pentyl, hexyl and the like.

20 The term " C_{2-6} alkenyl" refers to a straight or branched chain alkyl moiety having two to six carbon atoms and having in addition one double bond, of either E or Z stereochemistry where applicable. This term would include for example, vinyl, 1-propenyl, 1- and 2- butenyl, 2- methyl-2-propenyl etc.

25 The term " C_{2-6} alkynyl" refers to a straight or branched chain alkyl moiety having two to six carbon atoms and having in addition one triple bond. This term would include for example, ethynyl, 1-propynyl, 1- and 2- butynyl, 1- methyl-2-butynyl etc.

The term "cycloalkyl" refers to a saturated alicyclic moiety having from three to six carbon atoms and includes for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

30 The term "cycloalkenyl" refers to an alicyclic moiety having from three to six carbon atoms and having in addition one double bond. This term includes, for example, cyclopentenyl and cyclohexenyl.

The term "heterocycloalkyl" refers to a saturated heterocyclic moiety having from two to six carbon atoms and one or more heteroatom from the group N, O, S (or oxidised versions thereof) which may be optionally benzofused at any available position. This includes for example azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, benzodioxole
5 and the like. For the group NB₂, which is heterocycloalkyl, the saturated heterocyclic moiety must contain at least one N atom. This includes, for example, azetidinyl, pyrrolidinyl, piperidinyl and the like.

The term "heterocycloalkenyl" refers to an alicyclic moiety having from three to six carbon atoms and one or more heteroatoms from the group N, O, S and having in
10 addition one double bond. This term includes, for example, dihydropyranyl.

The term "aryl" refers to an aromatic carbocyclic radical having a single ring or two condensed rings, optionally substituted with an aryl group substituent. This term includes, for example phenyl or naphthyl.

The term "heteroaryl" refers to aromatic ring systems of five to ten atoms of which
15 at least one atom is selected from O, N and S, and optionally substituted with an aryl group substituent. This term includes for example furanyl, thiophenyl, pyridyl, indolyl, quinolyl and the like.

The term "aryl group substituent" refers to a substituent chosen from halogen, CN, CF₃, CHF₂, CH₂F, OCF₃, OCF₂H, OCFH₂ and NO₂.

20 The term "halogen" means fluorine, chlorine, bromine or iodine.

The term "benzofused" refers to the addition of a benzene ring sharing a common bond with the defined ring system.

The term "cycloimidyl" refers to a saturated ring of five to ten atoms containing the atom sequence -C(=O)NC(=O)-. The ring may be optionally benzofused at any
25 available position. Examples include succinimidoyl, phthalimidoyl and hydantoinyl.

The term "optionally substituted" means optionally substituted with one or more of the groups specified, at any available position or positions.

The terms "protected amino", "protected carboxy" and "protected hydroxamic acid" mean amino, carboxy and hydroxamic acid groups which can be protected in a
30 manner familiar to those skilled in the art. For example, an amino group can be protected by a benzyloxycarbonyl, *tert*-butoxycarbonyl, acetyl or like group, or may be in the form of a phthalimido or like group. A carboxyl group can be protected in the form of a

readily-cleavable ester such as the methyl, ethyl, benzyl or *tert*-butyl ester. A hydroxamic acid may be protected as either N or O-substituted derivatives, such as O-benzyl or O-*tert*-butyldimethylsilyl.


Salts of compounds of formula (I) include pharmaceutically-acceptable salts, for example acid addition salts derived from inorganic or organic acids, such as hydrochlorides, hydrobromides, p-toluenesulphonates, phosphates, sulphates, perchlorates, acetates, trifluoroacetates, propionates, citrates, malonates, succinates, lactates, oxalates, tartrates and benzoates.

Salts may also be formed with bases. Such salts include salts derived from inorganic or organic bases, for example alkali metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.

When the "protected carboxy" group in compounds of the invention is an esterified carboxyl group, it may be a metabolically-labile ester of formula CO_2R^9 where R^9 may be an ethyl, benzyl, phenethyl, phenylpropyl, " α or β -naphthyl, 2,4-dimethylphenyl, 4-*tert*-butylphenyl, 2,2,2-trifluoroethyl, 1-(benzyloxy)benzyl, 1-(benzyloxy)ethyl, 2-methyl-1-propionyloxypropyl, 2,4,6-trimethylbenzyloxymethyl or pivaloylmethyl group.

Compounds of the general formula (I) may be prepared by any suitable method known in the art and/or by the following processes. It will be appreciated that, where a particular stereoisomer of formula (I) is required, the synthetic processes described herein may be used with the appropriate homochiral starting material, and/or isomers can be resolved from mixtures using conventional separation techniques (e.g. HPLC). The compounds according to the invention may be prepared by the following process. In the description and formulae below the groups R^1 , R^2 and B are as defined above, and Y is NHOH , except where otherwise indicated. It will be appreciated that functional groups, such as amino, hydroxyl or carboxyl groups, present in the various compounds described below, and which it is desired to retain, may need to be in protected form before any reaction is initiated. In such instances, removal of the protecting group may be the final step in a particular reaction sequence. Suitable protecting groups for such functionality will be apparent to those skilled in the art. For specific details see Greene T.W. *et al*, "Protective Groups in Organic Synthesis", Wiley Interscience (1999).

Thus, for example, compounds of the invention may be prepared by the following general route:



- Acids of formula (IV), where X is for example an alkoxy group, e.g. methoxy or ethoxy or a chiral auxiliary, e.g. R-4-benzyl-oxazolidin-2-one, may be prepared by 5 deprotection of an ester of formula (VI) (where W is for example a *tert*-butyl or benzyl group) using, for example, an acid such as trifluoroacetic acid or by reaction with hydrogen in the presence of an appropriate catalyst such as palladium on carbon. Esters of formula (VI) may be prepared by reaction of an ester of formula (VII), wherein Z is an appropriate leaving group such as a halide, for example a bromide, or an alkyl or aryl 10 sulfonate such as methanesulfonate, with an ester of formula (VIII). Suitable conditions for this reaction include the treatment of compound (VIII) with a strong organic base, such as *n*-butyllithium or sodium hexamethyldisilazide, in an inert solvent such as tetrahydrofuran at an appropriate temperature such as -78°C to 0°C, followed by the slow addition of (VII).
- 15 Many esters of formulae (VII) and (VIII) or amines of formula (V) are known in the literature or may be prepared by standard methods known to those skilled in the art or by methods described in the examples hereinafter.

The acids of formula (IV) may be used to prepare compounds of formula (III) by reaction with an amine of formula B_2NH (V) using standard methods known to those skilled in the art, for example, by *in situ* activation of an acid of formula (IV) using for example a diimide such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 5 advantageously in the presence of catalyst such as 4-dimethylaminopyridine, in a halogenated hydrocarbon, e.g. dichloromethane, followed by subsequent addition of an amine of formula (V). Alternatively, an acid of formula (IV) may be activated, for example by conversion to an acid halide such as an acid chloride by reaction with a halogenating agent such as oxalyl chloride, in the presence of a catalyst such as *N,N*- 10 dimethylformamide in a halogenated hydrocarbon, e.g. dichloromethane. The acid chloride (which may or may not be isolated) can then be reacted with an amine of formula (V) in the presence of an amine base such as triethylamine in a halogenated hydrocarbon, e.g. dichloromethane.

Carboxylic acids of formula (II) may be prepared by deprotection of a suitably 15 protected carboxylic acid of formula (III), where X is removed for example by lithium hydroxide in the case of an alkyl ester, e.g. ethyl or lithium hydroxide/hydrogen peroxide in the case of a chiral auxiliary such as *R*-4-benzyl-oxazolidin-2-one, using appropriate solvent and temperature conditions such as those described in the examples hereinafter.

The acids of formula (II) may be used to prepare compounds of formula (I) under 20 conditions well known in the literature. For example, treatment of acids of formula (II) with oxalyl chloride in an inert solvent (such as dichloromethane) gives an intermediate acid chloride, which may or may not be isolated, but which in turn is reacted with hydroxylamine at a suitable temperature such as room temperature to give the desired hydroxamic acids (I). Alternatively, an acid of formula (II) maybe activated *in situ* using 25 for example a diimide such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, advantageously in the presence of a catalyst such as a N-hydroxy compound, e.g. N-hydroxybenzotriazole, using suitable conditions, e.g. in *N,N* dimethylformamide at -10°C, prior to the subsequent addition of a suitably protected hydroxylamine such as *tert*-butyldimethyl silyl hydroxylamine and maybe an amine base 30 such as N-methylmorpholine followed by warming to ambient temperature. The protecting group maybe removed using appropriate conditions, such as water or tetrabutylammonium

fluoride and acetic acid in tetrahydrofuran at 0°C, to yield the desired hydroxamic acids of formula (I).

Compounds of formula (I) may also be prepared by interconversion of other compounds of formula (I). Thus, for example, a compound of formula (I) wherein is a C₁₋₆ alkyl group may be prepared by hydrogenation (using palladium on carbon in suitable solvent, such as an alcohol, e.g. ethanol) of a compound of formula (I) wherein R¹ is a C₂₋₆ alkenyl group.

Any mixtures of final products or intermediates obtained can be separated on the basis of the physico-chemical differences of the constituents, in known manner, into the pure final products or intermediates, for example by chromatography, distillation, fractional crystallization, or by formation of a salt if appropriate or possible under the circumstances.

The compounds according to the invention exhibit *in vitro* inhibiting activities with respect to the stromelysin, collagenase, gelatinase, ADAM or ADAM-TS enzymes. Compounds according to the invention may also exhibit *in vitro* inhibition of membrane shedding events known to be mediated by metalloproteinases, for example, α-APP, ACE, TGF-α, TNF-α, Fas ligand, selectins, TNFR-I, TNFR-II, CD30, IL-6R, CD43, CD44, CD16-I, CD16-II, Folate receptor, CD23, or IL-1RII.

The activity and selectivity of the compounds may be determined by use of the appropriate enzyme inhibition test, for example as described in Examples A-M of WO-A-9805635, by the assay for the inhibition of CD23 shedding described in WO-A-9924399 or by the assay of TNF RI shedding described in WO-A-0056704.

This invention also relates to a method of treatment for patients (including man and/or mammalian animals raised in the dairy, meat or fur industries or as pets) suffering from disorders or diseases which can be attributed to metalloproteinases.

Accordingly, the compounds of formula (I) can be used among other things in the treatment of osteoarthritis and rheumatoid arthritis, and in diseases and indications resulting from the over-expression of these matrix metalloproteinases such as found in certain metastatic tumour cell lines.

As mentioned above, compounds of formula (I) are useful in human or veterinary medicine since they are active as inhibitors of TNF and MMPs. Accordingly in another aspect, this invention concerns:

a method of management (by which is meant treatment or prophylaxis) of disease or conditions mediated by TNF and/or MMPs in mammals, in particular in humans, which method comprises administering to the mammal an effective amount of a compound of formula (I) above, or a pharmaceutically acceptable salt thereof; and

5 a compound of formula (I) for use in human or veterinary medicine, particularly in the management (by which is meant treatment or prophylaxis) of diseases or conditions mediated by TNF and/or MMPs; and

the use of a compound of formula (I) in the preparation of an agent for the management (by which is meant treatment or prophylaxis) of diseases or conditions
10 mediated by TNF and/or MMPs.

The disease or conditions referred to above include inflammatory diseases, autoimmune diseases, cancer, cardiovascular diseases, diseases involving tissue breakdown. Appropriate diseases include rheumatoid arthritis, osteoarthritis, osteoporosis, neurodegeneration, Alzheimer's disease, stroke, vasculitis, Crohn's disease,
15 ulcerative colitis, multiple sclerosis, periodontitis, gingivitis and those involving tissue breakdown such as bone resorption, haemorrhage, coagulation, acute phase response, cachexia and anorexia, acute infections, HIV infections, fever, shock states, graft versus host reactions, dermatological conditions, surgical wound healing, psoriasis, atopic dermatitis, epidermolysis bullosa, tumour growth, angiogenesis and invasion by secondary
20 metastases, ophthalmological disease, retinopathy, corneal ulceration, reperfusion injury, migraine, meningitis, asthma, rhinitis, allergic conjunctivitis, eczema, anaphylaxis, restenosis, congestive heart failure, endometriosis, atherosclerosis, endosclerosis, aspirin-independent anti-thrombosis, systemic lupus erythematosus and solid organ transplant.

Compounds of formula (I) may also be useful in the treatment of pelvic
25 inflammatory disease (PID), age-related macular degeneration and cancer-induced bone resorption. Further, they can be used in the treatment of lung diseases, e.g. selected from cystic fibrosis, adult respiratory distress syndrome (ARDS), emphysema, bronchitis obliterans-organising pneumonia (BOOP), idiopathic pulmonary fibrosis (PIF), diffuse alveolar damage, pulmonary Langerhan's cell granulomatosis, pulmonary
30 lymphangioleiomyomatosis (LAM) and chronic obstructive pulmonary disease (COPD).

For the treatment of all disorders or diseases previously indicated, the compounds of formula (I) may be administered orally, topically, parenterally, by inhalation spray or

rectally in dosage unit formulations containing non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, 5 sheep, dogs, cats etc, the compounds of the invention are effective in the treatment of humans.

The pharmaceutical composition containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups 10 or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active 15 ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, 20 for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glycetyl monostearate or glycetyl distearate may be employed. They may also be coated by the techniques described in the US Patents 25 4,256,108; 4,166,452; and 4,265,874, to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules where in the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is 30 mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending

agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example 5 polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such a polyoxyethylene with partial esters derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate. The aqueous suspensions may also contain 10 one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral 15 oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

20 Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified, for example sweetening, flavouring and colouring agents, may also be present.

25 The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally- occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soya bean, lecithin, and esters or partial 30 esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate and condensation products of the said partial esters with ethylene oxide, for example

polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, 5 a preservative and flavouring and colouring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be in a sterile injectable solution or suspension in a non-toxic 10 parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland 15 fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The compounds of formula (I) may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary 20 temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

For topical use, creams, ointments, jellies, solutions or suspensions, etc containing the compounds of Formula (I) are employed. For the purposes of this specification, topical application includes mouth washes and gargles.

Dosage levels of the order of from about 0.05 mg to about 140 mg per kilogram 25 of body weight per day are useful in the treatment of the above- indicated conditions (about 2.5 mg to about 7 g per patient per day). For example, inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day (about 0.5 mg to about 3.5 g per patient per day). The amount of active ingredient that may be combined with the carrier materials to 30 produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may vary from about 5 to about 95% of the total composition. Dosage unit

forms will generally contain between about 1 mg to about 500 mg of active ingredient.

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

The following Examples illustrate the invention.

Intermediate 1 2-(2-(4-(4-Chlorobenzoyl)piperidin-1-yl)-2-oxoethyl)-4-methylpentanoic acid methyl ester

4-(4-Chlorobenzoyl)piperidine (0.2 g) was added to a solution of methyl 3-isobutylsuccinic acid (0.15 g) and EDC (0.25 g) in dichloromethane (10 ml) and the solution was stirred for 18 h, then washed with water (10 ml), aqueous citric acid (10 ml), saturated sodium bicarbonate (10 ml) and brine (10 ml), dried over magnesium sulphate (1 g) and evaporated to give the title compound (0.25 g) as a colourless solid.

R_f 0.45 (ether)

Intermediate 2 2-(2-(4-(4-Chlorobenzoyl)piperidin-1-yl)-2-oxoethyl)-4-methylpentanoic acid

A solution of Intermediate 1 (0.25 g) in tetrahydrofuran (5 ml) was treated with a solution of lithium hydroxide (0.1 g) in water (5 ml) and the mixture was stirred at room temperature for 24 hours, then evaporated *in vacuo*, the aqueous residue washed with ether (2 x 5 ml), acidified with dilute HCl and extracted with ethyl acetate (3 x 10 ml). The solvent was washed with water (10 ml) and brine (10 ml), dried over magnesium sulphate (1 g) and evaporated to give the title compound (0.18 g) as a colourless solid.

R_f 0.28 (EtOAc)

Intermediate 3 2-(2-(4-(4-Chlorobenzoyl)piperidin-1-yl)-2-oxoethyl)-4-methylpentanoic acid N-*tert*-butyldimethylsilyloxyamide

A solution of Intermediate 2 (0.18 g) in DCM (10 ml) was treated with EDC (0.15 g) and O-*tert*-butyldimethylsilylhydroxylamine (0.15 g) and the mixture was stirred for 18 h, then washed with water (10 ml) and brine (10 ml), dried over magnesium sulphate (1 g) and evaporated to give the title compound as a colourless solid (0.12 g).

R_f 0.64 (EtOAc)

Intermediate 4 **4R-Benzyl-3-(3-methylbutyryl)oxazolidin-2-one**

n-Butyllithium (33.0 ml, 1.6 M) was added to a solution of 4R-benzyloxazolidin-2-one (9.0 g) in tetrahydrofuran (100 ml) at -78 °C and the solution was stirred for 30 min, then a solution of isovaleryl chloride (6.1 g) was added dropwise over 20 min. The 5 resulting suspension was stirred for 2 h, then aqueous ammonium chloride (50 ml) was added and the mixture evaporated *in vacuo*. The product was collected by filtration, washed with water (15 ml) and dried in *vacuo* to give the title compound (13 g) as a colourless solid.

R_f 0.45 (2:1 ether/hexane)

10 **Intermediate 5** **3S-(4R-Benzyl-2-oxo-oxazolidine-3-carbonyl)-4-methyl-pentanoic acid *tert*-butyl ester**

Sodium hexamethyldisilazide (1.0 M in tetrahydrofuran, 23.0 ml) was added to a solution of Intermediate 4 (6.0 g) in tetrahydrofuran at -78 °C and the solution was stirred for 30 min, then a solution of *tert*-butyl bromoacetate (3.7 ml) in tetrahydrofuran was 15 added dropwise. The mixture was stirred for 30 min, then allowed to warm to room temperature and ammonium chloride solution (5 ml) added. The mixture was evaporated *in vacuo* and the aqueous residue extracted with dichloromethane (3 x 10 ml). The solvent was washed with water (15 ml), brine (15 ml), dried over magnesium sulphate (5 g) and evaporated to give the title compound (8.6 g) as a colourless solid.

20 R_f 0.65 (3:2 hexane/ether)

Intermediate 6 **3S-(4R-Benzyl-2-oxo-oxazolidine-3-carbonyl)-4-methyl-pentanoic acid**

Trifluoroacetic acid (10 ml) was added to a solution of Intermediate 5 (8.6 g) in dichloromethane (50 ml) and the solution was stirred at room temperature for 2 h, then 25 evaporated in *vacuo* and the residue azeotroped with heptane to dryness. The residue was dissolved in aqueous sodium bicarbonate (10 ml) and washed with ether (2 x 10 ml), the aqueous layer acidified with citric acid and extracted with dichloromethane (3 x 10 ml). The solvent was washed with water (10 ml) and brine (10 ml), dried over magnesium sulphate (5 g) and evaporated to give the title compound as a colourless oil (7.2 g) which 30 crystallised slowly on standing.

R_f 0.45 (ether + 1% AcOH)

Intermediate 7 **4-(4-Chlorophenylsulfanyl)piperidine-1-carboxylic acid *tert*-butyl ester**

Di-*tert*-carbonate (9 g) was added to a stirred suspension of 4-bromopiperidine (10 g) in dichloromethane (200 ml). Triethylamine (6.3 ml) was added and the reaction stirred at room temperature for 30 min, before being washed with aqueous citric acid (5%, 100 ml), water (100 ml) and brine (100 ml). The organic layer was dried over magnesium sulphate (5 g), before the solvent was removed *in vacuo* to yield a colourless oil which was taken up in *N,N*-dimethylformamide (50 ml). 4-Chlorothiophenol (5.8 g) and potassium carbonate (5.3 g) were added and the reaction heated at 80 °C for 6 h. On cooling the reaction was diluted with water (50 ml) and extracted with ether (3 x 50 ml). The combined organic extracts were washed with water (100 ml), brine (100 ml), dried over magnesium sulphate (2 g), and the solvent removed *in vacuo* to yield the title compound (14.2 g) as a yellow oil.

R_f 0.43 (2:1 hexane/ether)

Intermediate 8 **4-(4-Chlorobenzenesulfonyl)piperidine-1-carboxylic acid *tert*-butyl ester**

Oxone (25 g) and sodium acetate (9 g) in water (200 ml) were added to a solution of Intermediate 7 (14.2 g) in methanol (300 ml) and the reaction stirred at room temperature for 6 h. The methanol was removed *in vacuo* and the resulting slurry extracted with dichloromethane (2 x 100 ml). The combined organic extracts were washed with aqueous sodium hydroxide (2M, 100 ml), water (100 ml), brine (100 ml), dried over magnesium sulphate (3 g) and the solvent removed *in vacuo*. The oily residue was crystallized from ether/hexane to yield on filtration and drying *in vacuo* the title compound as a white solid (7.2 g).

R_f 0.29 (ether)

Intermediate 9 **4-(4-Chlorobenzenesulfonyl)piperidine**

Trifluoroacetic acid (15 ml) was added to a solution of Intermediate 8 (6.5 g) in dichloromethane (40 ml) and the solution was stirred at room temperature for 3 h, then evaporated *in vacuo* and the residue azeotroped with heptane to dryness. The residue was dissolved in aqueous sodium bicarbonate (10 ml) and washed with ether (2 x 10 ml), the aqueous layer acidified with citric acid and extracted with

dichloromethane (3 x 10 ml). The dichloromethane extracts were combined and washed with water (10 ml), brine (10 ml), dried over magnesium sulphate (5 g) and evaporated to give the title compound as a white solid (5.0 g).

R_f 0.25 (EtOAc with 1% ammonium hydroxide)

5 **Intermediate 10** **4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidine-1-carboxylic acid
tert-butyl ester**

Di-*tert*-carbonate (0.9 g) was added to a stirred suspension of (2,4-difluorophenyl)piperidin-4-ylmethanone (1 g) in dichloromethane (30 ml). Triethylamine (0.62 ml) was added and the reaction stirred at room temperature for 2 h, before being 10 washed with aqueous citric acid (5%, 20 ml), water (20 ml) and brine (20 ml). The organic layer was dried over magnesium sulphate (1 g), before the solvent was removed in *vacuo* to yield a yellow oil which was taken up in ethanol (20 ml). Acetic acid (2 ml) and aqueous hydroxylamine (2 ml) were added and the reaction stirred at room 15 temperature for 2 h. Water (50 ml) was added and the reaction extracted with dichloromethane (3 x 30 ml). The combined organic extracts were washed with water (50 ml), brine (50 ml), dried over magnesium sulphate (2 g), and the solvent removed in *vacuo* to yield a yellow oil which was taken up in *N,N*-dimethylformamide (20 ml) and sodium hydride (0.12 g, 60%) added. The reaction was heated to 80°C for 3 h, before on cooling being diluted with water (40 ml), and extracted with EtOAc (3 x 20 ml). The combined organic extracts were washed with water (30 ml), brine (30 ml), 20 dried over magnesium sulphate (1 g) and the solvent removed in *vacuo* to yield the title compound (0.7 g) as a white solid.

R_f 0.63 (ether)

Intermediate 11 **6-Fluoro-3-piperidin-4-ylbenzo[d]isoxazole**

25 Trifluoroacetic acid (8 ml) was added to a solution of Intermediate 10 (0.7 g) in dichloromethane (20 ml) and the solution was stirred at room temperature for 3 h, then evaporated in *vacuo* and the residue azeotroped with heptane to dryness. The residue was dissolved in methanol (4 ml), diluted with ether (ca 12 ml) and the solid that formed was collected by filtration. On drying in *vacuo*, the title compound was 30 yielded as a pink solid (0.65 g).

R_f 0.25 (7% MeOH/dichloromethane with 1% ammonium hydroxide).

Intermediate 12 **4-(Naphthalen-2-yloxy)piperidine-1-carboxylic acid *tert*-butyl ester**

To a stirred solution of 2-naphthol (2.9 g) and 4-hydroxypiperidine-1-carboxylic acid *tert*-butyl ester (4 g) in tetrahydrofuran (30 ml) at 0 °C was added 5 triphenylphosphine (5.2 g) and diethyl azodicarboxylate (3.2 ml). The reaction was allowed to warm to room temperature and stirred for 16 h. The solvent was removed *in vacuo* and the slurry taken up in EtOAc (30 ml) and washed with aqueous sodium hydroxide (1M, 2 x 30 ml), water (30 ml) and brine (30 ml). The organic extract was diluted with hexane (50 ml), and the precipitates were removed by filtration, and the 10 filtrate dried over magnesium sulphate (1 g). The solvent was removed *in vacuo* to yield the title compound as a white solid (3.4 g).

R_f 0.63 (2:1 ether/hexane).

Intermediate 13 **4-(Naphthalen-2-yloxy)piperidine hydrochloride**

Trifluoroacetic acid (20 ml) was added to a solution of Intermediate 12 (3.4 g) 15 in dichloromethane (60 ml) and the solution was stirred at room temperature for 1 h, then evaporated *in vacuo* and the residue azeotroped with heptane to dryness. The residue was dissolved in aqueous sodium hydroxide (1M, 10 ml) and washed with ether (2 x 10 ml), the aqueous layer acidified with citric acid and extracted with dichloromethane (3 x 10 ml). The solvent was washed with water (10 ml), brine (10 ml), dried over magnesium sulphate (2 g) and evaporated to give a yellow oil. The oil 20 was taken up in methanol (5 ml) and hydrogen chloride in ether (2M, 15 ml) was added. The precipitate was collected by filtration and dried *in vacuo* to yield the title compound as a white solid (2.6 g).

R_f 0.05 (10% MeOH/dichloromethane)

Intermediate 14 **1-(4*R*-Benzyl-2-oxo-oxazolidin-3-yl)-4-[4-(4-chlorobenzoyl)-piperidin-1-yl]-2*S*-isopropylbutane-1,4-dione**

EDC (0.20 g) was added to a solution of Intermediate 6 (0.32 g) in dichloromethane (20 ml) and the solution was stirred for 30 min, then a solution of 4-(4-chlorobenzoyl)piperidine (0.25 g) was added and the mixture was stirred overnight. 30 The solution was washed with aqueous citric acid (10 ml), aqueous sodium bicarbonate (10 ml) and brine (10 ml), dried over magnesium sulphate (1 g) and evaporated to give the title compound (0.50 g) as a colourless gum.

R_f 0.47 (ether).

Similarly prepared were:

Intermediate 15 **1-(4R-Benzyl-2-oxo-oxazolidin-3-yl)-4-[4-(4-chlorophenoxy)-piperidin-1-yl]-2S-isopropylbutane-1,4-dione**

From (4*R*, 3*R*) 3-(4-benzyl-2-oxo-oxazolidine-3-carbonyl)-4-methylpentanoic acid (0.62 g) and 4-chlorophenoxy piperidine (0.58 g), the title compound was yielded as a colourless solid (1.1 g).

R_f 0.48 (ether)

Intermediate 16 **1-(4R-Benzyl-2-oxo-oxazolidin-3-yl)-4-[4-(4-chlorophenyl)-piperazin-1-yl]-2S-isopropylbutane-1,4-dione**

From Intermediate 6 (1.7 g) and 4-chlorophenylpiperazine (1.4 g), the title compound was yielded as a colourless foam (2.50 g).

R_f 0.39 (ether)

Intermediate 17 **1-(4R-Benzyl-2-oxo-oxazolidin-3-yl)-4-[4-(4-chlorobenzene-sulfonyl)piperidin-1-yl]-2S-isopropylbutane-1,4-dione**

From Intermediate 6 (1.02 g) and Intermediate 9 (0.85 g), the title compound was yielded as a white foam (1.46 g).

R_f 0.73 (ether)

Intermediate 18 **1-(4R-Benzyl-2-oxo-oxazolidin-3-yl)-4-[4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]-2S-isopropylbutane-1,4-dione**

From Intermediate 6 (0.16 g) and Intermediate 11 (0.18 g), the title compound was yielded as a yellow oil (0.12 g).

R_f 0.45 (2:1 ether/hexane)

Intermediate 19 **1-(4R-Benzyl-2-oxo-oxazolidin-3-yl)-2S-isopropyl-4-[4-(naphthalen-2-yloxy)piperidin-1-yl]butane-1,4-dione**

From Intermediate 6 (0.31 g) and Intermediate 13 (0.26 g), the title compound was yielded as a yellow oil (0.32 g).

R_f 0.63 (2:1 ether/hexane)

Intermediate 20 **2S-{2-[4-(4-Chlorobenzoyl)piperidin-1-yl]-2-oxoethyl}-3-methylbutyric acid**

Lithium hydroxide (0.15 g) in water (5 ml) was added to a solution of Intermediate 14 (1.8 g) in tetrahydrofuran (20 ml), water (5 ml) and aqueous hydrogen peroxide (8M, 1.3 ml) at 0 °C and the mixture was stirred for 18 h. Sodium sulfite (5 g) in water (10 ml) was added and the mixture was evaporated *in vacuo*. The aqueous

residue was washed with ether (2×10 ml), then acidified with citric acid and extracted with dichloromethane (2×20 ml), the combined dichloromethane extracts were washed with water (30 ml), brine (30 ml), dried over magnesium sulphate (1 g) and evaporated to give the title compound (0.65 g) as a colourless solid.

5 R_f 0.25 (EtOAc)

Similarly prepared were:

Intermediate 21 $2S\text{-}\{2\text{-[4-(4-Chlorophenoxy)piperidin-1-yl]-2-oxoethyl}\}\text{-3-methylbutyric acid}$

From Intermediate 15 (1.1 g), to yield the title compound as a colourless solid (0.65 g).

10 R_f 0.40 (EtOAc)

Intermediate 22 $2S\text{-}\{2\text{-[4-(4-Chlorophenyl)piperazin-1-yl]-2-oxoethyl}\}\text{-3-methylbutyric acid}$

From Intermediate 16 (2.50 g) as a colourless solid (0.80 g).

15 R_f 0.20 (ether + 1% AcOH)

Intermediate 23 $2S\text{-}\{2\text{-[4-(4-Chlorobenzenesulfonyl)piperidin-1-yl]-2-oxoethyl}\}\text{-3-methylbutyric acid}$

From Intermediate 17 (1.46 g), to yield the title compound as a white solid (0.6 g).

20 R_f 0.43 (EtOAc)

Intermediate 24 $2S\text{-}\{2\text{-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]-2-oxoethyl}\}\text{-3-methylbutyric acid}$

From Intermediate 18 (112 mg), to yield the title compound as a white solid (0.6 g).

25 R_f 0.25 (ether)

Intermediate 25 $2S\text{-3-Methyl-2-[2-[4-(naphthalen-2-yloxy)piperidin-1-yl]-2-oxoethyl}]\text{-butyric acid}$

From Intermediate 19 (0.32 g), to yield the title compound as a beige oil (0.12 g).

R_f 0.35 (2:1 EtOAc/hexane)

30 **Example 1** $2S\text{-}\{2\text{-[4-(4-Chlorobenzoyl)piperidin-1-yl]-2-oxoethyl}\}\text{-4-methylpentanoic acid N-hydroxy amide}$

A solution of Intermediate 3 (0.12 g) was stirred in DCM (10 ml) and a solution of HCl in ether (2 ml) was added dropwise. The mixture was stirred for 10 min, then

diluted with hexane (10 ml) and the product isolated by filtration to give the title compound as colourless solid.

R_f 0.35 (10% MeOH/CH₂Cl₂).

MS 379, 381 (M+1)

- 5 **Example 2** **2S-{2-[4-(4-Chlorobenzoyl)piperidin-1-yl]-2-oxoethyl}-3-methylbutyric acid N-hydroxy amide**

EDC (0.20 g) and N-hydroxybenzotriazole (0.15 g) were added to a solution of Intermediate 20 (250 mg) in DMF (10 ml) at -10 °C and the mixture was stirred for 30 min, then a solution of *tert*-butyldimethyl silyl hydroxylamine (120 mg) and N-methylmorpholine (200 µl) was added. The mixture stirred for 48 h, then added to water (10 ml) and extracted with EtOAc (2 x 10 ml). The solvent was washed with water (10 ml), aqueous sodium bicarbonate (10 ml), brine (10 ml), dried over magnesium sulphate (1 g) and evaporated and the residue purified by chromatography (6% MeOH/DCM) to give the title compound (120 mg) as colourless solid.

15 R_f 0.42 (6% MeOH/CH₂Cl₂)

MS 380 (M⁺)

Similarly prepared were:

- Example 3** **2S-{2-[4-(4-Chlorophenoxy)piperidin-1-yl]-2-oxoethyl}-3-methylbutyric acid N-hydroxy amide**

20 From Intermediate 21 (93 mg), to yield the title compound as a colourless solid (30 mg).

R_f 0.37 (10% MeOH/CH₂Cl₂)

MS 368 (M⁺)

- Example 4** **2S-{2-[4-(4-Chlorophenyl)piperazin-1-yl]-2-oxoethyl}-3-methylbutyric acid N-hydroxy amide**

25 From Intermediate 22 (0.80 g), to yield the title compound as a beige foam (0.43 g).

R_f 0.37 (6% MeOH/CH₂Cl₂)

MS 353 (M⁺)

Example 5 **2S-{2-[4-(4-Chlorobenzenesulfonyl)piperidin-1-yl]-2-oxoethyl}-3-methylbutyric acid N-hydroxy amide**

From Intermediate 23 (0.80 g), followed by purification by flash chromatography on silica (eluent 6% MeOH/CH₂Cl₂) to yield the title compound as a
5 white solid (0.20 g).

R_f 0.29 (6% MeOH/CH₂Cl₂)

MS 417 (M⁺)

Example 6 **2S-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]-2-oxoethyl}-3-methylbutyric acid N-hydroxy amide**

10 From Intermediate 24 (0.70 g), followed by purification by flash chromatography on silica (eluent 6% MeOH/CH₂Cl₂) to yield the title compound as a white solid (0.43 g).

R_f 0.33 (5% MeOH/CH₂Cl₂)

MS 380 (M+1)

15 **Example 7** **2S-N-Hydroxy-3-methyl-2-{2-[4-(naphthalen-2-yloxy)-piperidin-1-yl]-2-oxo-ethyl}butyramide**

From Intermediate 25 (0.10 g), followed by purification by flash chromatography on silica (eluent 10% MeOH/CH₂Cl₂) to yield the title compound as a white solid (0.035 g).


20 R_f 0.37 (10% MeOH/CH₂Cl₂)

MS 385 (M+1)

CLAIMS

1. A compound of formula (I)

5



10 wherein

R¹ is a group (optionally substituted with R³) selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, C₁₋₆ alkyl-aryl, heteroaryl, C₁₋₆ alkyl-heteroaryl, cycloalkyl, C₁₋₆ alkyl-cycloalkyl, heterocycloalkyl and C₁₋₆ alkyl-heterocycloalkyl; and

R² is H or C₁₋₆ alkyl;

15 or CR¹R² is cycloalkyl or heterocycloalkyl optionally substituted with R³ or a group (optionally substituted with R³) selected from C₁₋₆ alkyl, aryl, C₁₋₆ alkyl-aryl, heteroaryl and C₁₋₆ alkyl-heteroaryl;

20 R³ is OR⁷, COR⁷, CO₂R⁶, CON(R⁷)₂, N(R⁷)₂, NR⁷COR⁷, NR⁷CON(R⁷)₂, NR⁷CO₂R⁸, NR⁷SO₂R⁸, S(O)₀₋₂R⁸ and SO₂N(R⁷)₂; or cycloimidyl (optionally substituted with R⁴)

R⁴ is C₁₋₆ alkyl;

B-N-B is heterocycloalkyl optionally substituted with R⁵ or =NOR⁵;

25 R⁵ is H, R⁶ or a group (optionally substituted with R⁶) selected from C₁₋₆ alkyl, aryl, C₁₋₆ alkyl-aryl, heteroaryl, C₁₋₆ alkyl-heteroaryl, cycloalkyl, C₁₋₆ alkyl-cycloalkyl, heterocycloalkyl and C₁₋₆ alkyl-heterocycloalkyl;

R⁶ is H or a group selected from N(R⁷)₂, NR⁷COR⁷, NR⁷CON(R⁷)₂, NR⁷CO₂R⁸, NR⁷SO₂R⁸, OR⁷, COR⁷, CO₂R⁴, CON(R⁷)₂, S(O)₀₋₂R⁸ and SO₂N(R⁷)₂;

30 R⁷ is H or a group selected from C₁₋₆ alkyl, aryl, C₁₋₆ alkyl-aryl, heteroaryl, C₁₋₆ alkyl-heteroaryl, cycloalkyl, C₁₋₆ alkyl-cycloalkyl, heterocycloalkyl and C₁₋₆ alkyl-heterocycloalkyl, wherein said group is optionally substituted with R⁸, COR⁸, S(O)₀₋₂R⁸, CO₂R⁸, OR⁸, CONR⁴R⁸, NR⁶R⁸ or SO₂NR⁴R⁸, and for each case of N(R⁷)₂ the R⁷ groups are the same or different or N(R⁷)₂ is heterocycloalkyl optionally substituted with R⁸, COR⁸, S(O)₀₋₂R⁸, CO₂R⁸, OR⁸, CONR⁴R⁸, NR⁶R⁸ or SO₂NR⁴R⁸; and

- are the same or different or N(R⁷)₂ is heterocycloalkyl optionally substituted with R⁸, COR⁸, S(O)₀₋₂R⁸, CO₂R⁸, OR⁸, CONR⁴R⁸, NR⁶R⁸ or SO₂NR⁴R⁸; and
R⁸ is C₁₋₆ alkyl, aryl, C₁₋₆ alkyl-aryl, heteroaryl or C₁₋₆ alkyl-heteroaryl;
or a salt, solvate, hydrate, N-oxide, protected amino, protected carboxy or
protected hydroxamic acid derivative thereof.
5. A compound of claim 1, wherein R¹ is C₁₋₆ alkyl.
2. A compound of claim 1 or claim 2, wherein R² is H.
3. A compound of claim 1, wherein CR¹R² is optionally substituted cycloalkyl or heterocycloalkyl.
10. 5. A compound of any preceding claim, which is in the form of a single enantiomer or diastereomer.
6. A compound of claim 1, which is selected from
2S-{2-[4-(4-chlorobenzoyl)piperidin-1-yl]-2-oxoethyl}-4-methylpentanoic acid
N-hydroxy amide,
15. 2S-{2-[4-(4-chlorobenzoyl)piperidin-1-yl]-2-oxoethyl}-3-methylbutyric acid
N-hydroxy amide,
2S-{2-[4-(4-chlorophenoxy)piperidin-1-yl]-2-oxoethyl}-3-methylbutyric acid
N-hydroxy amide, and
2S-{2-[4-(4-chlorophenyl)piperazin-1-yl]-2-oxoethyl}-3-methylbutyric acid
20. N-hydroxy amide.
7. A compound of claim 1, selected from
2S-{2-[4-(4-chlorobenzenesulfonyl)piperidin-1-yl]-2-oxoethyl}-3-methylbutyric
acid N-hydroxy amide,
2S-{2-[4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]-2-oxoethyl}-3-
25. methylbutyric acid N-hydroxy amide, and
2S-N-hydroxy-3-methyl-2-{2-[4-(naphthalen-2-yloxy)-piperidin-1-yl]-2-oxo-
ethyl}butyramide.
8. A pharmaceutical composition for use in therapy, comprising a compound as
defined in any preceding claim, and a pharmaceutically-acceptable diluent or carrier.

9. Use of a compound according to any of claims 1 to 7, for the manufacture of a medicament for the treatment or prevention of cancer, asthma, inflammation, an inflammatory condition, an autoimmune, infectious or ocular disease, or age-related macular degeneration.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/04865

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7	C07D211/32	C07D295/18	A61K31/445	A61K31/495	A61P11/00
	A61P19/00	A61P25/00			

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 892 112 A (GROBELNY DAMIAN ET AL) 6 April 1999 (1999-04-06) cited in the application column 44, line 5; claims ----	1,8,9
A	WO 97 24117 A (RHONE POULENC RORER PHARMA ;GRONEBERG ROBERT D (US); NEUENSCHWANDE) 10 July 1997 (1997-07-10) cited in the application claims 1,22,61-70 ----	1,8,9
A	FR 2 597 865 A (ROUSSEL UCLAF) 30 October 1987 (1987-10-30) cited in the application page 15 -page 17; claims; example 8 -----	1,8,9

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed Invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

9 March 2001

21/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax. (+31-70) 340-3016

Authorized officer

Bosma, P

INTERNATIONAL SEARCH REPORT

Information on patent family members

Interr	ial Application No
PCT/GB	00/04865

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
US 5892112 A	06-04-1999	US 5270326 A US 5114953 A US 5268384 A US 5239078 A US 5189178 A US 5183900 A AU 1000399 A AU 1604995 A CA 2158760 A EP 0690841 A JP 9501183 T WO 9519965 A US 5773438 A AU 6554294 A AU 8311898 A CA 2160139 A EP 0692931 A JP 8511509 T WO 9422309 A AT 164767 T AU 652016 B AU 9135191 A CA 2096223 A DE 69129236 D DE 69129236 T EP 0558681 A ES 2115668 T JP 6102626 B NO 931803 A WO 9209282 A AT 197667 T AU 3433293 A DE 69329699 D EP 0663823 A JP 7503007 T WO 9313741 A US 5696147 A AT 157963 T AU 661289 B AU 9089791 A CA 2096225 A DE 69127630 D DE 69127630 T EP 0558635 A ES 2109335 T JP 7080825 B JP 6511468 T NO 931844 A WO 9209563 A AU 662504 B	14-12-1993 19-05-1992 07-12-1993 24-08-1993 23-02-1993 02-02-1993 04-03-1999 08-08-1995 27-07-1995 10-01-1996 04-02-1997 27-07-1995 30-06-1998 24-10-1994 28-01-1999 13-10-1994 24-01-1996 03-12-1996 13-10-1994 15-04-1998 11-08-1994 25-06-1992 22-05-1992 14-05-1998 17-09-1998 08-09-1993 01-07-1998 14-12-1994 18-05-1993 11-06-1992 15-12-2000 03-08-1993 28-12-2000 26-07-1995 30-03-1995 22-07-1993 09-12-1997 15-09-1997 20-07-1995 25-06-1992 21-02-1993 16-10-1997 09-04-1998 08-09-1993 16-01-1998 30-08-1995 22-12-1994 09-07-1993 11-06-1992 07-09-1995	
WO 9724117 A	10-07-1997	AU 1529897 A EP 0871439 A JP 2000503012 T US 6057369 A	28-07-1997 21-10-1998 14-03-2000 02-05-2000	
FR 2597865 A	30-10-1987	NONE		